Literature DB >> 11097033

Interrelation of lymphocyte subpopulations in peripheral blood under cervical papillomavirus infection.

V P Lakatosh, L M Lazarenko, L M Lyanenko, M V Azarskova, O M Mikhailenko, L Tkáciková, A M Boroda.   

Abstract

T(CD3+)-, B(CD19+)-lymphocytes and their subsets (CD4+, CD8+, CD3+ DR+, CD3- DR+) in peripheral blood of patients with CIN I, CIN II, CIN III and cancer in situ associated with HPV infection were evaluated. In peripheral blood of women with CIN II, CIN III and cancer in situ the number of T-lymphocytes which expressed CD3+ DR+ antigen decreased. In patients with CIN I, CIN III and cancer in situ the level of the CD4+ cells decreased; the level of the CD8+ cells increased. These patients had a lower CD4/CD8 ratio, the number of B cells being standard. The results may have important implications in the prognosis and immunotherapy of HPV infection.

Entities:  

Mesh:

Year:  1999        PMID: 11097033     DOI: 10.1007/BF02825669

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.629


  14 in total

Review 1.  [The current concepts of papillomavirus infection and its role in the pathogenesis of pretumorous and tumorous processes of the cervix uteri].

Authors:  V P Lakatosh; L M Lazarenko; L O Lianenko; V Ie Dubchak
Journal:  Lik Sprava       Date:  1999-03

2.  Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patients.

Authors:  A.N. Fiander; M. Adams; A.S. Evans; A.J. Bennett; L.K. Borysiewicz
Journal:  Int J Gynecol Cancer       Date:  1995-11       Impact factor: 3.437

Review 3.  Immunity to human papillomavirus-associated cervical neoplasia.

Authors:  P L Stern
Journal:  Adv Cancer Res       Date:  1996       Impact factor: 6.242

Review 4.  Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms.

Authors:  T C Wu; R J Kurman
Journal:  J Natl Cancer Inst       Date:  1997-02-05       Impact factor: 13.506

5.  Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection.

Authors:  M Clerici; M Merola; E Ferrario; D Trabattoni; M L Villa; B Stefanon; D J Venzon; G M Shearer; G De Palo; E Clerici
Journal:  J Natl Cancer Inst       Date:  1997-02-05       Impact factor: 13.506

6.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.

Authors:  M Clerici; N I Stocks; R A Zajac; R N Boswell; D R Lucey; C S Via; G M Shearer
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

7.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

8.  Treatment of cervical intraepithelial neoplasia reverses CD4/CD8 lymphocyte abnormalities in peripheral venous blood.

Authors:  W.P. Soutter; V. Kesic
Journal:  Int J Gynecol Cancer       Date:  1994-07       Impact factor: 3.437

9.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Authors:  L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

Review 10.  [Malpighian epithelia and papillomavirus infections].

Authors:  Y Chardonnet; F Béjui-Thivolet; J Viac
Journal:  Pathol Biol (Paris)       Date:  1992-03
View more
  2 in total

1.  Production of interferons and change of the lymphocyte subpopulation phenotype in peripheral blood at cervical papillomavirus infection.

Authors:  L Lazarenko; M Spivak; V Lakatosh; L Kryvokhatska; O Mikhailenko; A Rudenko; L Tkáciková; I Mikula
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099

Review 2.  Chronic immune activation and inflammation as the cause of malignancy.

Authors:  K J O'Byrne; A G Dalgleish
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.